Tirzepatide, semaglutide, and liraglutide vs DPP4i were associated with lower risk of alcohol use disorder, especially among men and younger patients.
The medications seem to dampen the effects of drugs ranging from nicotine to alcohol—but scientists haven’t been able to ...
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...
A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight ...
A new deal with major drugmakers, unveiled by U.S. President Donald Trump on Thursday, aims to expand coverage and cut prices ...
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This ...
In 2023, 48.5 million people ages 12 or older in the U.S. contended with a substance use disorder or disorders -- for almost 29 million, it was an alcohol use disorder (AUD) and around 27 million ...
This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...
Savannah Chrisley is getting candid about her body goals amid her ongoing weight loss journey, saying she wants to be skinny.
HealthDay on MSN
American College of Gastroenterology, Oct. 24-29
The annual meeting of the American College of Gastroenterology was held from Oct. 24 to 29 in Phoenix, attracting participants from around the world, including gastroenterology and digestive disease ...
The Hearty Soul on MSN
New Research Uncovers Unexpected Health Gains From GLP‑1 Medications
Heart failure with preserved ejection fraction, or HFpEF, is now the most common form of heart failure. Many people who ...
NextPlat Corp ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback